Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:43 PM
Ignite Modification Date:
2025-12-24 @ 9:43 PM
NCT ID:
NCT02823132
Eligibility Criteria:
Inclusion Criteria :
* persons who have provided written consent
* Patients with national health insurance cover
* Patients with malignant hemopathy who have been treated with chemotherapy able to induce profound neutropenia (PN \< 500 / mm3) lasting more than 10 days.
* Patients with malignant hemopathy who have received an autologous bone marrow graft
* Patients with severe idiopathic medullar aplasia (PN \< 500 / mm3) who need to be hospitalized for at least 10 consecutive days (with or without treatment with immunosuppressants)
Exclusion Criteria:
* Patients who have received an bone marrow PSC allograft (as such patients have a risk of aspergillosis, which appears in most cases after medullar recovery; they will not be included in the study).
* Patients who have received an autologous PSC graf (as the duration of neutropenia is in most cases less than 10 days).
* Patients whose neutropenia, retrospectively assessed, lasted less than 10 days.
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT02823132
Study Brief:
Protocol Section:
NCT02823132